AU2021101366A4 - A method of preparation of ethanolic extract of IPOMEA reniformis chois in alloxan induced rats for antidiabetic effect - Google Patents
A method of preparation of ethanolic extract of IPOMEA reniformis chois in alloxan induced rats for antidiabetic effect Download PDFInfo
- Publication number
- AU2021101366A4 AU2021101366A4 AU2021101366A AU2021101366A AU2021101366A4 AU 2021101366 A4 AU2021101366 A4 AU 2021101366A4 AU 2021101366 A AU2021101366 A AU 2021101366A AU 2021101366 A AU2021101366 A AU 2021101366A AU 2021101366 A4 AU2021101366 A4 AU 2021101366A4
- Authority
- AU
- Australia
- Prior art keywords
- chois
- ipomea
- alloxan
- preparation
- ethanolic extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method of preparation of ethanolic extract of IPOMEA reniformis chois in alloxan
induced rats for antidiabetic effect
The present invention relates to a method of preparation of ethanolic extract of IPOMEA
reniform is chois in alloxan induced rats for antidiabetic effect. Antidiabetic activity of ethanolic
extract of leaves of pomearenformisChois. was studied on alloxan induced diabetic rats as two
different doses were studied. It showed significant reduction in the blood glucose level.
Concurrent histopathological examination of pancreas of these animals showed comparable
regeneration by ethanolic extracts (lower and higher dose) which were earlier, necroses by
alloxan.
Description
A method of preparation of ethanolic extract of IPOMEA reniformis chois in alloxan induced rats for antidiabetic effect
Technical field of invention:
Present invention in general relates to a method of preparation of ethanolic extract of IPOMEA reniformis chois in alloxan induced rats for antidiabetic effect.
Background of the invention:
The background information herein below relates to the present disclosure but is not necessarily prior art.
Diabetes is a disorder of the chemical reaction that is necessary for proper utilization of carbohydrates, fats and proteinfrom the diet, along with inadequate secretion or lack of insulin. Insulin is a hormone produced by the pancreas to regulate the amount of sugar in the blood. Ipomoearenformis chois (Convolvulaceae) is a perennial, much branched herb (creeper).
It is found widely distributed all over the India, specially in damp places in upper gangetic plain, Gujarat, Bihar, West Bengal, Western- Ghats, ascending up to 900m in the hills, Goa, Karnatak a in India, Ceylon and Tropical Africa.
It is reported to have many important medicinal properties. In the Indigenous system of Medicine, Ipomoea renformis has been claimed to be useful for cough, headache, neuralg ia, rheumatism, diuretic, inflammation, troubles of nose, fever due to enlargement of liver an d also in kidney diseases. Powder of leaves is used as a snuff during epileptic seizures, Juice act as purgative and the root is having diuretic, laxative, and applied in the disease of the gums. The whole plant decoction is mainly responsible for its medicinal uses.
Objective of the invention:
An objective of the present invention is to attempt to overcome the problems of the prior art and provide a method of preparation of ethanolic extract of IPOMEA reniformis chois in alloxan induced rats for antidiabetic effect.
Summary of the invention:
Accordingly following invention provides a method of preparation of ethanolic extract of IPOMEA reniformis chois in alloxan induced rats for antidiabetic effect. Antidiabetic activity of ethanolic extract of leaves of IpomearenformisChois. was studied on alloxan induced diabetic rats as two different doses were studied. It showed significant reduction in the blood glucose level. Concurrent histopathological examination of pancreas of these animals showed comparable regeneration by ethanolic extracts (lower and higher dose) which were earlier, necroses by alloxan
Detailed description of the invention:
The present invention relates to a method of preparation of ethanolic extract of IPOMEA reniformis chois in alloxan induced rats for antidiabetic effect.
Material and Method
Plant material: The leaves of the plant were dried under shade andthen coarsely powdered with help of mechanical grinder. Thepowder was passed through sieve no. 40 and stored in anairtight container for further studies. Extraction was carried out by continuous soxhlet extraction process for 72 hr.
Animals: Swiss albino mice (20-25g) and wistar rats (150-200g) of either sex and of approximate same age used in thepresent study was procured. The animals were fed with standard pellet diet (Hindustan Lever Ltd., Bangalore) and waterad libitum. All the animals were kept under alternate cycle ofl2 hrs of darkness and light. The animals were acclimatizedto the laboratory condition for 1 week before starting theexperiment. The experimental protocols were approved byInstitutional Animal Ethics Committee (IAEC/CPD/415/07)after scrutinization. Mice were used to determine the LD50value (3000 mg/kg).
Sample collection: The blood samples were collectedfor the measurement of blood glucose level from the tail vein6and estimated using electronic glucometer (on-call now) andglucostix.
Alloxan monohydrate (BDH) 150 mg/kg bodyweights were dissolved in normal saline and injected intraperitoneally after 18 hrs. Fasting to induce hyperglycemicgroup.After one hour of alloxan administration the animalswere fed on standard pellets and water ad libitum. The experimental animals were fasted for 18 hr. before alloxan injection. The blood glucose level (BGL) was monitored afteralloxanization in blood sample collected by tail tipping methodusing a glucometer.After 72 hr. the rats having BGL above150 mg/dl of blood were selected for the study and the animals were divided into five groups and each group contained6 rats.
Group - I served as normal and received normal saline solution. Group-II received alloxan monohydrates (150 mg/kg). Group III received alloxan and standard antidiabetic drug i.e.Glibenclamide (5 mg/kg P.0). Group IV and V received alloxan and ethanolic extracts of leaves of IpomeareformisChois.
(i.e.700 and 1000 mg/kg P.O.) The blood glucoselevels were monitored after initial 3,6 and 12 hr. of administration of a single dose of the ethanolic extract and at the endof initial 3,6 and 12 days for prolonged treatment. On the12thday all the animals were sacrificed by over dose of etheranesthesia. The whole pancreas from each animal was removedafter sacrificing the animal & collected in % formalin solution and immediately processed by the paraffin technique section of 5 micron thickness were cut and stained byhaematoxylin and eosin for histological examination.
Statistical Analysis:Dunnett's multiple comparison test,was carried out and * P < 0.5 was considered as significant.Groups were compared with control group.
The hypoglycemic effect of ethanolic extracts ofleaves of IpomeareniformisChois. was investigated in alloxaninduced diabetic rats and the results are expressed in Tablel and 2. The BGL of fasted rats were measured at initial 3'd, 6thand 12thhours and initial 3'd, 6th and12th day after treatment with Glibenclamide and ethanolicextracts when compared with standard drug Glibenclamide.
Table 1: Effect of Ipomoea reniformisChois.on blood glucose level of alloxan induced diabetic rats. Change of BGL of alloxan induced diabetic rats after days in Groups Treatment mg/dl Initial 3 rd 6 th 1 2 th
Normal D/W 1Oml/kg P.O 87.500 + 1.648 88.333 + 89.667+ 89.883+ 1.520** 1.994** 1.302** Diabetic D/W 10ml/kg P.O 410.17 + 1.38 450.17+ 466.83+ 505.83
+ control 1.138** 2.52 1.078 Positive Glibenclamide 391.50 + 1.727 319.17+ 258.33+ 128.50+ control 5mg /kg P.O 1.249** 2.17** 1.478** LDAE 700 mg/kg P.O 404.83 + 359.00 + 314.00+ 194.67+ 1.014 1.713* 1.713** 0.918** HDAE 1000mg/kg P.O 396.33+ 338.3+ 276.67+ 157.17+ 0.8819 0.988** 1.520** 1.352** n = 6, * P < 0.05, **P<0.01, Values are expressed as mean + SEM
Table 2: Effect of aqueous extract of Ipomoea reniformisChois.on serum profile of alloxan induced diabetic rats after 12 days of treatment. Groups Treatment HDL LDL CHO VLDL TG Normal D/W 10ml/kg P.O. 40.000± 15.833± 67.500± 14.00± 66.833± 1.211 0.945 1.893 0.930 1.950 Diabetic D/W 10ml/kg P.O. 28.333± 48.833± 103.00±2 39.167± 129.17± control 1.054 2.157 .160 1.851 2.725 Standard Glibenclamide 83.167± 23.333± 75.667± 19.500± 83.832± 0.5mg/kg P.O. 0.914 0.881 1.382 0.763 1.662 LDAE 700mg/kg P.O 30.167± 35.500± 36.000± 33.333± 111.19± 0.914 0.885 1.592 0.881 1.815 HDAE 1000mg/kg P.O 83.500± 30.333± 86.167± 28.607± 90.000± 0.763 0.14 1.515 0.666 2.129
Based on the literature survey and information obtained about it medicinal use in folkore medicine. This plantwas selected. The phytochemical and pharmacological studieswere done on the ethanolic extracts of leaves of Ipomeareniformis Chois. The leaves of the plant were separated, driedand powdered and extracted by continuous soxhlet apparatus. In these extract the phytochemical constituents were identified by chemical test and these test showed the presence ofmany active component like tannins, saponins, phenolic compound sterol, flavonoid, glycoside and phytosterols. Since ethanolic extract of leaves of IpomeareformisChois.showed the presence of many phytoconstituents, it wasselected for the pharmacological study.The antidiabetic activity was evaluated by using alloxan induced diabetic rats. Since the ethanolic extract of leavesof IpomearenformisChois. Showed significant antidiabeticactivity, thus it can be suggested that formation of insulin shouldhave been increased by the ethanolic extract.
Since the present study revealed that the leaves ofIpomeareformisChois.wasfoundto possess significant antidiabetic activity when compared to standard drug. Thesefactors support the use of the plant in traditional folklore medicine.
Claims (1)
1. A method of preparation of ethanolic extract of IPOMEA reniformis chois in alloxan induced rats for antidiabetic effect, comprises of following steps;
a) a leaves of the IpomearenformisChois. are drying under shade and then coarsely powdered with help of mechanical grinder;
b) powdered passed through sieve no. 40 and stored; and
c) extraction carried out by continuous soxhlet extraction process for 72 hr.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021101366A AU2021101366A4 (en) | 2021-03-16 | 2021-03-16 | A method of preparation of ethanolic extract of IPOMEA reniformis chois in alloxan induced rats for antidiabetic effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021101366A AU2021101366A4 (en) | 2021-03-16 | 2021-03-16 | A method of preparation of ethanolic extract of IPOMEA reniformis chois in alloxan induced rats for antidiabetic effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021101366A4 true AU2021101366A4 (en) | 2021-05-13 |
Family
ID=75829053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021101366A Ceased AU2021101366A4 (en) | 2021-03-16 | 2021-03-16 | A method of preparation of ethanolic extract of IPOMEA reniformis chois in alloxan induced rats for antidiabetic effect |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2021101366A4 (en) |
-
2021
- 2021-03-16 AU AU2021101366A patent/AU2021101366A4/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eddouks et al. | Caraway and caper: potential anti-hyperglycaemic plants in diabetic rats | |
| Moqbel et al. | Antidiabetic properties of Hibiscus rosa sinensis L. leaf extract fractions on non-obese diabetic (NOD) mouse | |
| Nyunaï et al. | Hypoglycaemic and antihyperglycaemic activity of Ageratum conyzoides L. in rats. | |
| Deshmukh et al. | Antihyperglycaemic activity of alcoholic extract of Aerva lanata (L.) AL Juss. Ex JA Schultes leaves in alloxan induced diabetic mice | |
| Hossain et al. | Hypolipidemic and hepatoprotective effects of different fractions of ethanolic extract of immature leaves of Mangifera indica (Linn.) in alloxan induced diabetic rats | |
| Arika et al. | Hypoglycemic effect of Lippia javanica in alloxan induced diabetic mice | |
| CN108440292B (en) | Sapium sebiferum element A-H, pharmaceutical composition and application thereof | |
| CN1203083C (en) | Rhizoma anemarrhenae extract and preparation process and use thereof | |
| CN104922173B (en) | The application of le dish extract inhibition alpha-glucosidase | |
| AU2021101366A4 (en) | A method of preparation of ethanolic extract of IPOMEA reniformis chois in alloxan induced rats for antidiabetic effect | |
| CN101982184A (en) | Preparation method of taraxacum extract | |
| Tanko et al. | Anti-diabetic properties of Securinega virosa (Euphorbiaceae) leaf extract | |
| CN100536868C (en) | Powder injection contg high content tanshin polyphenolic acid salts, and its preparation method | |
| CN108314620B (en) | Sapium sebiferum elements I and J, and pharmaceutical composition and application thereof | |
| CN1771977A (en) | Notoginseng glycol-saponin composition and its prepn and use | |
| CN1209155C (en) | Balsam pear products containing multiple hypoglycemic active composition and preparation thereof | |
| CN1771978A (en) | Notoginseng triol-saponin composition and its prepn and use | |
| JP2000511166A (en) | Extract purified from harpagophytum procumbens and / or harpagophytum zeilidens, method for producing the same and use thereof | |
| Sivagnanam et al. | Anti-diabetic activity of oncocalyxone a isolated from prenanthes sarmentosus | |
| Patil et al. | Antihyperglycemic and hypoglycemic effect of Ficus racemosa leaves | |
| CN102188465A (en) | Preparation method of hedera plant extractives and purposes thereof | |
| CN111920799A (en) | Kulecuo effective component composition and preparation method and application thereof | |
| Maharana et al. | Anti-Hyperglycemic potential of aqueous extract of leaves of Solanum nigrum Linn | |
| CN1475222A (en) | Vine leaf extract and its preparation process | |
| Tiwari et al. | Pharmacological Modeling and Study for Antidiabetic Activity of Praecitrullus fistulosus Leaves Extracts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGI | Letters patent sealed or granted (innovation patent) | ||
| MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |